Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Thermogenesis is a medical devices business based in the US. Thermogenesis shares (THMO) are listed on the NASDAQ and all prices are listed in US Dollars. Thermogenesis employs 39 staff and has a trailing 12-month revenue of around $10.2 million.
Finder Award
SoFi Invest
tastyworks
| Latest market close | $5.08 |
|---|---|
| 52-week range | $2.67 - $45.00 |
| 50-day moving average | $4.41 |
| 200-day moving average | $11.57 |
| Wall St. target price | $45.00 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-0.91 |
*Signup bonus information updated weekly.
Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.
Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $5.08 from 2023-01-25
| 1 week (2023-01-19) | 43.50% |
|---|---|
| 1 month (2022-12-27) | 78.25% |
| 3 months (2022-10-27) | 4,980.00% |
| 6 months (2022-07-27) | 2,440.00% |
| 1 year (2022-01-27) | 497.65% |
|---|---|
| 2 years (2021-01-27) | 88.85% |
| 3 years (2020-01-27) | 5.33 |
| 5 years (2018-01-26) | 72.21% |
| Revenue TTM | $10.2 million |
|---|---|
| Gross profit TTM | $3.5 million |
| Return on assets TTM | -17.47% |
| Return on equity TTM | -213.24% |
| Profit margin | -102.6% |
| Book value | $7.33 |
| Market capitalisation | $3.5 million |
TTM: trailing 12 months
We're not expecting Thermogenesis to pay a dividend over the next 12 months.
Thermogenesis's shares were split on a 1:45 basis on 21 December 2022. So if you had owned 45 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Thermogenesis shares – just the quantity. However, indirectly, the new 4400% higher share price could have impacted the market appetite for Thermogenesis shares which in turn could have impacted Thermogenesis's share price.
Over the last 12 months, Thermogenesis's shares have ranged in value from as little as $2.67 up to $45. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Thermogenesis's is 2.5368. This would suggest that Thermogenesis's shares are significantly more volatile than the average for this exchange and represent a higher risk.
ThermoGenesis Holdings, Inc. develops, commercializes, and markets a range of automated technologies for chimeric antigen receptor (CAR-T) and other cell-based therapies. It markets a suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology, including its semi-automated, functionally closed CAR-TXpress platform, which streamlines the manufacturing process for the emerging CAR-T immunotherapy market. The company manufactures and markets AXP II Automated Cell Separation System, an automated cell separation system for isolating stem and progenitor cells from umbilical cord blood; and BioArchive Automated Cryopreservation System, an automated, robotic, liquid nitrogen controlled-rate-freezing, and cryogenic storage system for cord blood samples and cell therapeutic products used in clinical applications. It offers PXP Point-of-Care System, an automated sterile system for the automated processing of autologous peripheral blood or bone marrow aspirate derived stem cells at the point-of-care, such as surgical centers or clinics; PXP-LAVARE System, an automated system designed to wash, re-suspend, and volume reduce cell suspensions; PXP-1000 System, an automated system for fast and reproducible separation of multiple cellular components from blood with minimal red blood cell contamination; and X-Series products, such as X-Lab for cell isolation, X-Wash System for cell washing and reformulation, X-Mini for small scale cell purification, and X-BACS System under development for large scale cell purification. It also provides CAR-TXpress Platform that addresses the critical unmet need for large scale cellular processing and chemistry, manufacturing, and controls needs. The company was formerly known as Cesca Therapeutics Inc.
Everything we know about the TXO Energy IPO, plus information on how to buy in.
Everything we know about the Brera IPO, plus information on how to buy in.
What you need to know about investing in the leading indicator for the overall US stock market.
Buying an IPO is as simple as buying any other stock, but not every trading platform offers IPO stocks.
Steps to owning and managing NVOS, with 24-hour and historical pricing before you buy.
Your simple and straightforward guide to ETFs, how they work and the different types available.
Find out how stock lending works, the extra income you could potentially earn and the risks you should be aware of. Plus, compare stock trading platforms that offer stock lending.
Everything we know about the SONDORS IPO, plus information on how to buy in.
Everything we know about the Bullfrog AI Holdings IPO, plus information on how to buy in.
Learn about stock analysis and how to use it to find the right company to buy.
